<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025662</url>
  </required_header>
  <id_info>
    <org_study_id>010162</org_study_id>
    <secondary_id>01-H-0162</secondary_id>
    <nct_id>NCT00025662</nct_id>
    <nct_alias>NCT00016484</nct_alias>
  </id_info>
  <brief_title>Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS</brief_title>
  <official_title>Ex Vivo Selective Depletion of Alloreactive Donor T-Lymphocytes Using &quot;RFT5-SMPT-dgA&quot;: Reducing GVHD Risk Associated With Matched, Nonmyeloablative, Stem Cell Transplant for Hematologic Malignancies in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and effectiveness of stem cell transplantation in which&#xD;
      the donors T lymphocytes have undergone &quot;selective depletion.&quot; Certain patients with cancers&#xD;
      of the blood undergo transplantation of donated stem cells to generate new and normally&#xD;
      functioning bone marrow. In addition to producing the new bone marrow, the donor's&#xD;
      T-lymphocytes also fight any tumor cells that might have remained in the body. This attack on&#xD;
      tumor cells is called a &quot;graft-versus-leukemia&quot; (GVL) effect. However, another type of&#xD;
      T-lymphocyte from the donor may cause what is called &quot;graft-versus-host-disease&quot; (GVHD), in&#xD;
      which the donor cells recognize the patient's cells as foreign and mount an immune response&#xD;
      to reject them. Selective depletion is a technique that was developed to remove the&#xD;
      T-lymphocytes that cause harmful GVHD, while keeping those that produce the desirable GVL&#xD;
      effect.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite improved prophylaxis and treatment, graft-versus-host disease (GVHD) remains a major&#xD;
      complication after allogeneic stem cell transplantation. Although the most effective way to&#xD;
      prevent GVHD is T cell depletion, this process results in poor immune function leading to&#xD;
      increased rates of relapse, graft rejection, and post-transplant infections. Ideally, a&#xD;
      method of removing GVHD- producing effector cells while retaining a broad T cell repertoire,&#xD;
      including preservation of 3rd party, antiviral and anti-tumor responses would be desirable.&#xD;
      Preclinical studies from our lab have demonstrated that alloreactive T cells can be&#xD;
      selectively removed from the donor lymphocyte pool in vitro with the use of a specific&#xD;
      immunotoxin directed against the interleukin-2 receptor.&#xD;
&#xD;
      To test this clinically, we will perform nonmyeloablative allogeneic stem cell transplants in&#xD;
      older patients with hematologic malignancies. Although these patients can be cured with this&#xD;
      approach, they have significant morbidity and mortality from GVHD. At our institution,&#xD;
      nonmyeloablative transplantation is associated with an incidence of grade II-IV acute GVHD of&#xD;
      approximately 50%. Although well tolerated in younger patients, patients over the age of 50&#xD;
      years have a transplant-related mortality (TRM) of approximately 35%, which is mostly related&#xD;
      to GVHD. Through selective depletion of alloreactive donor lymphocytes, we hope to reduce&#xD;
      GVHD mortality, while preserving the transplant efficacy.&#xD;
&#xD;
      Patients receive a reduced intensity preparative regimen, followed by a mobilized peripheral&#xD;
      blood stem cell allograft from an HLA-identical sibling donor, containing&#xD;
      &quot;selectively-depleted&quot; donor lymphocytes. To obtain such a graft, colony stimulating factor&#xD;
      (G-CSF)-mobilized peripheral blood from the donor undergoes a positive cluster of&#xD;
      differentiation (CD34) selection followed by a negative T cell selection using the &quot;Nexell&quot;&#xD;
      Isolex 300i system. This stem cell-rich, T cell-depleted product will contain a CD34+ cell&#xD;
      dose of at least 5x10(6)/kg. The unabsorbed fraction, remaining after the positive CD34&#xD;
      selection, is then co-cultured for 72 hours with irradiated lymphocytes from the patient. The&#xD;
      immunotoxin, RFT5-SMPT-dgA, is added during the last 24 hours of culture to remove&#xD;
      alloreacting cells. The washed T cell product (CD3+ cell dose of 1-4 x 10(8)/kg) is&#xD;
      cryopreserved. Following the preparative regimen, the patient receives successive infusions&#xD;
      of the stem cell product and selected lymphocytes. All patients receive standard post&#xD;
      transplant immunosuppression with cyclosporine for a minimum of 30 days, followed by dose&#xD;
      reduction depending on the degree of donor lymphocyte chimerism.&#xD;
&#xD;
      The primary end point of this study is the incidence and severity of acute GVHD. We will also&#xD;
      examine the incidence of chronic GVHD, engraftment, degree of donor-host chimerism,&#xD;
      transplant related morbidity and mortality, as well as disease-free and overall survival.&#xD;
      Stopping rules will minimize the risk of untoward or unexpected side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related Mortality</measure>
    <time_frame>100 days after stem cell infusion</time_frame>
    <description>Nonrelapse mortality in the first 100 days of transplant expressed as a percentage of the total subjects.&#xD;
This is different from outcome measure 3 (Cumulative Nonrelapse Mortality), which is cumulative non relapse mortality till December 2011.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Dec 2011.</time_frame>
    <description>Percent overall survival (actuarial) at analysis in Dec 2011.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Non Relapse Mortality</measure>
    <time_frame>Dec 2011.</time_frame>
    <description>Percent non relapse mortality (actuarial) at analysis in Dec 2011</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Acute GVHD (Any Grade) Using the CIBMTR Grading System.</measure>
    <time_frame>100 days from transplant</time_frame>
    <description>Proportion of patients with acute GVHD, grade 1 to 4</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute GVHD (Grade 3 or 4) Using the CIBMTR Grading System.</measure>
    <time_frame>100 days from transplant</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Graft vs Host Disease</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Leukemia</condition>
  <condition>Leukemia, Myeloid</condition>
  <condition>Leukemia, Myelomonocytic, Chronic</condition>
  <condition>Leukemia, Lymphocytic</condition>
  <condition>Lymphoma</condition>
  <condition>Lymphoma, Mantle-cell</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Hodgkin Disease</condition>
  <arm_group>
    <arm_group_label>RFT5-SMPT-dgA Isolex system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RFT5-SMPT-dgA, a specific anti-interleukin-2 receptor immunotoxin used in allogeneic stem cell transplantation (SCT) in older patients with hematologic malignancies using a graft manipulation process</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RFT5-SMPT-dgA</intervention_name>
    <description>A specific anti-interleukin-2 receptor immunotoxin</description>
    <arm_group_label>RFT5-SMPT-dgA Isolex system</arm_group_label>
    <other_name>anti-interleukin-2 receptor immunotoxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isolex system</intervention_name>
    <description>CD34 selection/ T cell depletion used this system</description>
    <arm_group_label>RFT5-SMPT-dgA Isolex system</arm_group_label>
    <other_name>Nexell Isolex system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        - INCLUSION CRITERIA: PATIENT&#xD;
&#xD;
          -  Ages 50-75 years&#xD;
&#xD;
          -  Relapsed CML in chronic or accelerated phase after therapy with STI-571 (Gleevec)&#xD;
&#xD;
          -  Acute lymphoblastic leukemia (ALL), all patients in complete or partial remission.&#xD;
             Exceptions: T cell ALL&#xD;
&#xD;
          -  Acute myelogenous leukemia (AML): AML in first complete or partial remission including&#xD;
             AML secondary to chemotherapy or prior hematological disease such as myelodysplastic&#xD;
             syndrome, and myeloproliferative disorder.&#xD;
&#xD;
          -  Myelodysplastic syndromes: (1) refractory anemia with excess of blasts (RAEB), (2)&#xD;
             refractory anemia with excess blasts in transformation (RAEBT), (3) MDS with poor risk&#xD;
             cytogenetics defined by a complex karyotype (greater than or equal to three anomalies)&#xD;
             or chromosome 7 abnormalities, (4) secondary MDS after prior cytotoxic or radiation&#xD;
             therapy, or (5) chronic myelomonocytic leukemia (CMML)&#xD;
&#xD;
          -  Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia, refractory to&#xD;
             nucleoside analog therapy, with either progressive bulky disease or anemia (less than&#xD;
             10 g/dl) or thrombocytopenia (less than 100,000/microliter) not due to recent&#xD;
             chemotherapy&#xD;
&#xD;
          -  Mantle cell lymphoma&#xD;
&#xD;
          -  Relapsed intermediate- or high-grade non-Hodgkin's lymphoma: (1) post autologous&#xD;
             marrow or PBSC transplant, or (2) chemorefractory relapse. Exceptions: T cell NHL&#xD;
&#xD;
          -  Relapse Hodgkin's disease: (1) post autologous marrow or PBSC transplant, or (2)&#xD;
             chemorefractory relapse&#xD;
&#xD;
          -  Low-grade follicular or small lymphocytic lymphoma: (1) relapsed following&#xD;
             conventional chemotherapy, (2) relapsed following autologous marrow or PBSC&#xD;
             transplant, or (3) chemoresistant disease&#xD;
&#xD;
          -  Life expectancy greater than 3 months&#xD;
&#xD;
          -  Ability to comprehend the investigational nature of the study and provide informed&#xD;
             consent&#xD;
&#xD;
          -  Availability of an HLA-identical family donor, 18 to 75 years old&#xD;
&#xD;
          -  INCLUSION CRITERIA:&#xD;
&#xD;
        DONOR&#xD;
&#xD;
          -  HLA identical family donor, 18 to 75 years old&#xD;
&#xD;
          -  Fit to receive G-CSF and give peripheral blood stem cells (normal blood count,&#xD;
             normotensive, no history of stroke, no history of severe heart disease)&#xD;
&#xD;
          -  Ability to comprehend the investigational nature of the study and provide informed&#xD;
             consent&#xD;
&#xD;
          -  EXCLUSION CRITERIA:&#xD;
&#xD;
        RECIPIENT&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 3 or more&#xD;
&#xD;
          -  Major anticipated illness or organ failure incompatible with survival from PBSC&#xD;
             transplant&#xD;
&#xD;
          -  Diffusion Capacity fir carbon monoxide (DLCO) less than 60% predicted&#xD;
&#xD;
          -  Left ventricular ejection fraction less than 40%, or any angina.&#xD;
&#xD;
          -  Absolute lymphocyte count less than 300/mm(3)&#xD;
&#xD;
          -  Serum creatinine greater than 2.5 mg/dl&#xD;
&#xD;
          -  Serum bilirubin greater than 4 mg/dl, transaminases greater than 5x upper limit of&#xD;
             normal&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  Other malignant diseases liable to relapse or progress within 2 years&#xD;
&#xD;
          -  EXCLUSION CRITERIA:&#xD;
&#xD;
        DONOR&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  HIV positive. Donors who are positive for Hepatitis B Virus, Hepatitis C Virus or&#xD;
             human t-cell lymphoma virus (HTLV) will be used at the discretion of the investigator&#xD;
             and with appropriate consent of the recipient&#xD;
&#xD;
          -  Donor unfit to receive G-CSF and undergo apheresis (uncontrolled hypertension, history&#xD;
             of heart failure or unstable angina, platelet count less than 90,000/cu mm)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. J Barrett, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NHLBI, NIH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/detail/B_2001-H-0162.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Barrett J, Solomon S. The transition from bench to bedside: lessons learned in the creation of a new T-cell product for the clinic. Cytotherapy. 2004;6(6):593-5.</citation>
    <PMID>15764025</PMID>
  </reference>
  <reference>
    <citation>Solomon SR, Tran T, Carter CS, Donnelly S, Hensel N, Schindler J, Bahceci E, Ghetie V, Mich√°lek J, Mavroudis D, Read EJ, Vitetta ES, Barrett AJ. Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. Cytotherapy. 2002;4(5):395-406.</citation>
    <PMID>12473206</PMID>
  </reference>
  <reference>
    <citation>Mielke S, Solomon SR, Barrett AJ. Selective depletion strategies in allogeneic stem cell transplantation. Cytotherapy. 2005;7(2):109-15. Review.</citation>
    <PMID>16040390</PMID>
  </reference>
  <results_reference>
    <citation>Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R, Hensel N, Schindler J, Ghetie V, Leitman SF, Mai T, Carter CS, Kurlander R, Read EJ, Vitetta ES, Barrett AJ. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood. 2005 Aug 1;106(3):1123-9. Epub 2005 Apr 7.</citation>
    <PMID>15817673</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>April 20, 2011</results_first_submitted>
  <results_first_submitted_qc>December 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2012</results_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Blood Stem Cell</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Donor Apheresis</keyword>
  <keyword>Non-Myeloablative</keyword>
  <keyword>MDS</keyword>
  <keyword>Chronic Myeloid Leukemia</keyword>
  <keyword>CML</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>CLL</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>Hodgkin's Disease</keyword>
  <keyword>Mantle Cell Lymphoma</keyword>
  <keyword>Acute Myelogenous Leukemia (AML)</keyword>
  <keyword>Chronic Myeloid Leukemia (CML)</keyword>
  <keyword>Chronic Lymphocytic Leukemia (CLL)</keyword>
  <keyword>Myelodysplasia (MDS)</keyword>
  <keyword>Acute Lymphoblastic Leukemia (ALL)</keyword>
  <keyword>Bone Marrow Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Immunotoxins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment dates: 9/21/01 to 11/14/05 Location: Quaternary referral institute</recruitment_details>
      <pre_assignment_details>2 enrolled patients were not transplanted: one, because of donor refusal and the other because she was transplanted elsewhere</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>&quot;RFT5-SMPT-dgA&quot;, an Anti-interleukin, Used in Transplants</title>
          <description>Ex vivo selective depletion of alloreactive donor T lymphocytes utilizing &quot;RFT5-SMPT-dgA&quot;, a specific anti-interleukin-2 receptor immunotoxin in matched, nonmyeloablative, peripheral blood stem cell transplantation for hematologic malignancies in older adults</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22">One patient who received a transplant did not meet eligibility and was a special exemption.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical failure of manipulation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RFT5-SMPT-dgA, an Anti-interleukin, Used in Transplants</title>
          <description>Ex vivo selective depletion of alloreactive donor T lymphocytes utilizing RFT5-SMPT-dgA, a specific anti-interleukin-2 receptor immunotoxin in HLA-matched, nonmyeloablative, peripheral blood stem cell transplantation for hematologic malignancies in older adults</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment-related Mortality</title>
        <description>Nonrelapse mortality in the first 100 days of transplant expressed as a percentage of the total subjects.&#xD;
This is different from outcome measure 3 (Cumulative Nonrelapse Mortality), which is cumulative non relapse mortality till December 2011.</description>
        <time_frame>100 days after stem cell infusion</time_frame>
        <population>all 22 patients who received a selectively depleted allogeneic transplant, including one who was a special exemption for not meeting full eligibility criteria</population>
        <group_list>
          <group group_id="O1">
            <title>RFT5-SMPT-dgA, an Anti-interleukin, Used in Transplants</title>
            <description>Ex vivo selective depletion of alloreactive donor T lymphocytes utilizing RFT5-SMPT-dgA, a specific anti-interleukin-2 receptor immunotoxin in HLA-matched, nonmyeloablative, peripheral blood stem cell transplantation for hematologic malignancies in older adults</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-related Mortality</title>
          <description>Nonrelapse mortality in the first 100 days of transplant expressed as a percentage of the total subjects.&#xD;
This is different from outcome measure 3 (Cumulative Nonrelapse Mortality), which is cumulative non relapse mortality till December 2011.</description>
          <population>all 22 patients who received a selectively depleted allogeneic transplant, including one who was a special exemption for not meeting full eligibility criteria</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0" upper_limit="13.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Percent overall survival (actuarial) at analysis in Dec 2011.</description>
        <time_frame>Dec 2011.</time_frame>
        <population>all patients who received the selectively depleted transplant including one special exemption</population>
        <group_list>
          <group group_id="O1">
            <title>RFT5-SMPT-dgA, an Anti-interleukin, Used in Transplants</title>
            <description>Ex vivo selective depletion of alloreactive donor T lymphocytes utilizing RFT5-SMPT-dgA, a specific anti-interleukin-2 receptor immunotoxin in HLA-matched, nonmyeloablative, peripheral blood stem cell transplantation for hematologic malignancies in older adults</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Percent overall survival (actuarial) at analysis in Dec 2011.</description>
          <population>all patients who received the selectively depleted transplant including one special exemption</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Non Relapse Mortality</title>
        <description>Percent non relapse mortality (actuarial) at analysis in Dec 2011</description>
        <time_frame>Dec 2011.</time_frame>
        <population>All patients who received the selectively depleted transplant</population>
        <group_list>
          <group group_id="O1">
            <title>RFT5-SMPT-dgA, an Anti-interleukin, Used in Transplants</title>
            <description>Ex vivo selective depletion of alloreactive donor T lymphocytes utilizing RFT5-SMPT-dgA, a specific anti-interleukin-2 receptor immunotoxin in HLA-matched, nonmyeloablative, peripheral blood stem cell transplantation for hematologic malignancies in older adults</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Non Relapse Mortality</title>
          <description>Percent non relapse mortality (actuarial) at analysis in Dec 2011</description>
          <population>All patients who received the selectively depleted transplant</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" lower_limit="20.4" upper_limit="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Acute GVHD (Any Grade) Using the CIBMTR Grading System.</title>
        <description>Proportion of patients with acute GVHD, grade 1 to 4</description>
        <time_frame>100 days from transplant</time_frame>
        <population>All 22 subjects who received the selectively depleted transplant</population>
        <group_list>
          <group group_id="O1">
            <title>RFT5-SMPT-dgA, an Anti-interleukin, Used in Transplants</title>
            <description>Ex vivo selective depletion of alloreactive donor T lymphocytes utilizing RFT5-SMPT-dgA, a specific anti-interleukin-2 receptor immunotoxin in HLA-matched, nonmyeloablative, peripheral blood stem cell transplantation for hematologic malignancies in older adults</description>
          </group>
        </group_list>
        <measure>
          <title>Acute GVHD (Any Grade) Using the CIBMTR Grading System.</title>
          <description>Proportion of patients with acute GVHD, grade 1 to 4</description>
          <population>All 22 subjects who received the selectively depleted transplant</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" lower_limit="33.7" upper_limit="75.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Acute GVHD (Grade 3 or 4) Using the CIBMTR Grading System.</title>
        <time_frame>100 days from transplant</time_frame>
        <population>All 22 patients who received the selectively depleted transplant</population>
        <group_list>
          <group group_id="O1">
            <title>RFT5-SMPT-dgA, an Anti-interleukin, Used in Transplants</title>
            <description>Ex vivo selective depletion of alloreactive donor T lymphocytes utilizing RFT5-SMPT-dgA, a specific anti-interleukin-2 receptor immunotoxin in HLA-matched, nonmyeloablative, peripheral blood stem cell transplantation for hematologic malignancies in older adults</description>
          </group>
        </group_list>
        <measure>
          <title>Acute GVHD (Grade 3 or 4) Using the CIBMTR Grading System.</title>
          <population>All 22 patients who received the selectively depleted transplant</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse event reporting was collected for 7 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RFT5-SMPT-dgA, an Anti-interleukin, Used in Transplants</title>
          <description>Ex vivo selective depletion of alloreactive donor T lymphocytes utilizing RFT5-SMPT-dgA, a specific anti-interleukin-2 receptor immunotoxin in HLA-matched, nonmyeloablative, peripheral blood stem cell transplantation for hematologic malignancies in older adults</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Non relapse deaths</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Relapse deaths</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>A. John Barrett</name_or_title>
      <organization>NHLBI</organization>
      <phone>301-402-4170</phone>
      <email>barrettjj@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

